ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2026
Early Outcomes of Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Retrospective Analysis.
Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer is the most common cancer in US males. While conventional beam radiotherapy has been commonly used, there has been a shift toward hypofractionation, which involves using fewer higher-dose fractions over a shorter treatment course. Stereotactic body radiotherapy (SBRT) further condenses treatment to 5 fractions in < 2 weeks. Methods: This was a retrospective chart review of a veteran population with localized prostate cancer who received SBRT between November 2014 and October 2024 at the Kansas City Veterans Affairs Medical Center. Androgen deprivation therapy (ADT) or pelvic nodal irradiation with ADT was administered where indicated. Patients were included and followed for at least 24 months to assess efficacy and genitourinary (GU) and gastrointestinal (GI) toxicity using Radiation Therapy Oncology Group (RTOG) criteria. Cone-beam computed tomography was exclusively used for image-guided radiotherapy without the use of fiducials or hydrogel spacers. Results: A total of 174 patients met the inclusion criteria. The median age was 74 years, and the median prostate-specific antigen level was 11.9 ng/mL. Twenty-six patients had a Gleason score (GS) of 1, 77 had GS 2, 41 had GS 3, 18 had GS 4, and 12 had GS 5. Patients had a median follow-up of 45 months, and the disease-free survival and overall survival rates were 96.6% and 99.4%, respectively. There were 6 biochemical failures (3.4%), with 1 patient dying from metastatic cancer. The cumulative RTOG grade II and higher GU toxicity was 28.2% (26.4% grade II, 1.2% grade III, and 0.6% grade IV toxicity with rectovesical fistula requiring surgery). The cumulative RTOG grade II or higher GI toxicity rate was 3.4% with no grade III or IV complications. Conclusions: This retrospective analysis indicates that a short course of SBRT for localized prostate cancer demonstrates acceptable toxicity and promising early efficacy, even without the use of fiducials or hydrogel spacers. Longer follow-up is warranted to confirm these findings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.